UV Flu Technologies is focused on developing, manufacturing and distributing bio technology products initially targeting the indoor air quality industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis.
Increased media attention and growing public concern over the rise of flu pandemics, antibiotic resistant superbugs, asthma, allergies, tuberculosis, Sick Building Syndrome and toxic mold are encouraging governments, employers and homeowners to take further action to safeguard their health. As a result, the North American air purification equipment market is expected to expand significantly. In 2008, the indoor air quality market generated $7.7 billion.
Currently, UV Flu is primarily focused on selling and leasing its products directly or through distributors to medical accounts including hospitals, doctor and dentist offices, clinics and nursing homes. The company is leveraging longstanding contacts within the healthcare industry to drive placement. The team developed contacts with a number of large hospitals during its in-field product testing program.